A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
The use of the GLP-1R agonist semaglutide is revolutionizing the treatment of obesity, yet its mechanistic effects on energy balance remain elusive. Here, we demonstrate that reactivation of semaglutide-responsive dorsal vagal complex neurons mimics…
PURPOSE OF REVIEW: Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent among individuals with obesity, primarily due to metabolic dysfunction and structural cardiac remodeling. This review explores the emerging therapeuti…
INTRODUCTION: Semaglutide 2.4 mg injection (Wegovy), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved by the US Food and Drug Administration for weight management in June 2021. Tirzepatide, a glucose-dependent insulinotropic polypepti…
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medic…
BACKGROUND & AIMS: In phase 2 studies, efruxifermin, an Fc-FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with non-alcoholic steatohepatitis, now called metabolic dysfunction-associated steatohepatitis (MASH), for which…
With the rising prevalence of T2D worldwide, peripheral artery disease (PAD) now affects >230 million individuals globally. In the recent STRIDE trial, Bonaca et al.demonstrated that semaglutide improved walking capacity and hemodynamic parameters an…
BACKGROUND: Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance. However, f…
PURPOSE OF REVIEW: The "obesity paradox" describes the counterintuitive observation that overweight and mildly obese individuals with cardiovascular disease (CVD) may have better outcomes than those with normal weight. This paradox is particularly in…
IntroductionThe glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Semaglutide, have revolutionized the treatment of type 2 diabetes mellitus and obesity.Case desciptionThe aim of the present study was to report a case of Non-Arteritic Ant…
PURPOSE: The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications are widely prescribed for management of diabetes mellitus as well as obesity or weight management. Although there have been rare reports of skin hypersensitivity ass…
BACKGROUND: Nausea is one of the most reported side effect of GLP-1 receptor agonists (GLP-1a). Current recommendations fall short in taming the symptoms, include antiemetic medication, behavior changes, GLP-1a dose adjustment, and often cause a disr…
PURPOSE: This study comprehensively analyzed the global clinical trials and depicted a landscape for non-alcoholic fatty liver disease (NAFLD) therapy. METHODS: Using the Trialtrove database, we collected trial information of 2242 clinical trials. Us…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists (GIP/GLP-1 RAs) are emerging as effective treatments for obesity and cardiometabolic disease. This study evaluated physicia…
As obesity increases in the global population, it is important to recognize that obesity is not a willpower failure but a chronic disease regulated by genetic, environmental, and hormonal control of energy balance. Obesity is also caused by social an…
The onset of type 2 diabetes mellitus (T2DM) in prepubertal age is not uncommon nowadays. Here we are reporting on a young boy who was diagnosed with diabetes at the age of eight years. Diagnosis of diabetes was made based on symptoms of hyperglycemi…
Despite considerable advances in the systemic delivery of peptides, their susceptibility to gastrointestinal degradation and high molecular weight, which restricts permeability across biological barriers, remain obstacles to oral administration. As a…
The European Society of Cardiology annual congress is the premier global platform for dissemination and unraveling major scientific advances in the field of cardiology. Each year a myriad number of scientific ideas are exchanged at this meeting and m…